申请人:Taisho Pharmaceutical Co., Ltd.
                            
                            
                                公开号:EP4008405A1
                            
                            
                                公开(公告)日:2022-06-08
                            
                            
The present invention provides a compound represented by formula [I] having an LPA1 receptor-antagonizing action, or a pharmaceutically acceptable salt thereof.
                            本发明提供了一种由式[I]所表示的化合物,其具有LPA1受体拮抗作用,或其药学上可接受的盐。